IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by HF Advisory Group LLC

HF Advisory Group LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.4% in the third quarter, Holdings Channel reports. The firm owned 7,473 shares of the medical research company’s stock after selling 515 shares during the period. HF Advisory Group LLC’s holdings in IQVIA were worth $1,771,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the 2nd quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter valued at approximately $29,000. Finally, International Assets Investment Management LLC purchased a new position in shares of IQVIA in the second quarter worth $32,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Up 1.3 %

IQVIA stock opened at $212.96 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $190.20 and a 12 month high of $261.73. The stock has a market capitalization of $38.65 billion, a PE ratio of 27.95, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a 50 day simple moving average of $232.84 and a 200-day simple moving average of $229.54.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research analyst reports. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. BTIG Research cut their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.